ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1024

Number of Patients with Psoriatric Arthritis (PsA) in Germany Until 2040: Projection Based on Data from 65 Million People in the German Statutory Health Insurance

Philipp Sewerin1, stephanie Knippschild2, Sabrina Tulka2, Xenofon Baraliakos3 and Ralph Brinks2, 1Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 2Chair for Medical Biometry and Epidemiology, Witten, Germany, 3Rheumazentrum Ruhrgebiet Herne, Herne, Germany

Meeting: ACR Convergence 2022

Keywords: Epidemiology, prognostic factors, Psoriatic arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Session Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Recently, we have reported an increase in the incidence and prevalence of patients with PsA in Germany based on claim data from 65 million people in statutory health insurance during 2009 to 2012 [1]. The question of how these will develop in the future was nor answered, yet. We therefore performed a population-based estimation of long-term projection for incidence and prevalence of patients with diagnosis of PsA until the year 2040.

Methods: Based on prevalence and incidence of PsA, the number of men and women diagnosed with PsA until 2040 is projected using the illness-death model [2]. The mortality and age distribution of the general population is taken from the official population forecasts of the German Federal Statistical Office. Mortality of patients with PsA was considered by using estimates of the mortality rate ratios [3]. Percent change in projected case numbers refer to 2012 (base year).

Results: Starting from 2012, three scenarios about the incidence of PsA after 2012 were found (Graph): (A) increase of 5% per year as observed in [1], (B) no trend in incidence and (C) decrease of a similar 5% per year due to a theoretically anticipated early treatment effect. In scenario C, the number of men and women peaks at about 2028 and decreases slightly afterwards. The graph shows the projected numbers of men (left panel) and women (right) with PsA until 2040 in the three incidence scenarios. The projected numbers and the percent changes are given in the table.

Conclusion: Different scenario may be considered based on recent population data for the incidence course of PsA until 2040. The most optimistic scenario showed a trend of stabilization of incidence including the anticipated population mortality rates. Thus, it is likely that substantially more medical resources for treating patients with PsA are necessary in the next two decades, whereby approaches to the potential prevention of PsA, for example by very early treatment of psoriasis patients, should be further pursued.

Supporting image 1

Projection of incidences for men and women up to 2040 in three different scenarios.

Supporting image 2

The projected numbers and the percent changes are given in the table.


Disclosures: P. Sewerin, AXIOM Health, Amgen, AbbVie, Biogen, Bristol-Myers Squibb (BMS), Celgene, Chugai Pharma Marketing Ltd. / Chugai Europe, Deutscher Psoriasis-Bund,, Gilead Sciences, Hexal Pharma, Janssen-Cilag, Johnson & Johnson, Lilly / Lilly Europe / Lilly Global, medi-login, Mediri GmbH, Novartis Pharma, Onkowissen GmbH, Pfizer, Roche Pharma, Rheumazentrum Rhein- Ruhr, Sanofi-Genzyme, Spirit Medical Communication, Swedish Orphan Biovitrum, UCB Pharma; s. Knippschild, None; S. Tulka, None; X. Baraliakos, AbbVie, Lilly, Galapagos, MSD, Novartis, Pfizer, UCB, Bristol-Myers Squibb, Janssen, Roche, Sandoz, Sanofi; R. Brinks, None.

To cite this abstract in AMA style:

Sewerin P, Knippschild s, Tulka S, Baraliakos X, Brinks R. Number of Patients with Psoriatric Arthritis (PsA) in Germany Until 2040: Projection Based on Data from 65 Million People in the German Statutory Health Insurance [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/number-of-patients-with-psoriatric-arthritis-psa-in-germany-until-2040-projection-based-on-data-from-65-million-people-in-the-german-statutory-health-insurance/. Accessed February 4, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/number-of-patients-with-psoriatric-arthritis-psa-in-germany-until-2040-projection-based-on-data-from-65-million-people-in-the-german-statutory-health-insurance/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences